Objective:To explore the methods and effects of tumor injection of H101 guided by endoscopic ultrasonography(EUS)for patients with pancreatic carcinoma. Methods:A total of 92 patients with advanced pancreatic carcinoma were divided into the H101 group(n=40) and the chemotherapy group(n=52). The patients in the H101 group were treated by tumor injection of H101 guided by EUS complicated with gemcitabine and the patients in the chemotherapy group were treated only by gemcitabine. The changes of tumor body,VAS and KPS score,survival analysis,and adverse reaction were analyzed. Results:The partial remission (PR)rate and effective rate of the H101 group(40.0%,62.5%) was higher than those of the chemotherapy group (16.7%,20.0%) after 4,12 months of treatment(P < 0.05). The KPS score was elevated after 4,8 and 12 months of treatment and VAS score was decreased(P < 0.05),but there was no difference in the two groups(P > 0.05). The mortality of the H101 group (60.0%) in 12 months was decreased than that of the chemotherapy group(80.8%)(χ2=4.810,P=0.028). The mid-life span of the H101 group was(8.8 ± 0.5) months and prolonged than that of the chemotherapy group [(7.6 ± 0.4)months,χ2=3.976,P=0.046]. Conclusion:Tumor injection of H101 guided by EUS is safe and feasible for patients with advanced pancreatic carcinoma,and is helpful to improve the life quality and prolong life span.